Evidence map›Paper›PMID 38755180›Full record

ArticleNature communications2024

Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers.

Rebecca J Deyell, Yaoqing Shen, Emma Titmuss, Katherine Dixon, Laura M Williamson, Erin Pleasance, Jessica M T Nelson, Sanna Abbasi, Martin Krzywinski, Linlea Armstrong and 21 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Rebecca J Deyell *Department of Pediatrics, BC Children's Hospital and Research Institute, Vancouver, BC, Canada. rdeyell@cw.bc.ca.ORCID http://orcid.org/0000-0003-3315-4383
Yaoqing Shen *Canada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Emma Titmuss *Canada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-1993-6912
Katherine DixonCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Laura M WilliamsonCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Erin PleasanceCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-5104-042X
Jessica M T NelsonCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Sanna AbbasiCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Martin KrzywinskiCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Linlea ArmstrongDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Melika BonakdarCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-1437-1991
Carolyn Ch'ngCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0003-0323-4243
Eric ChuahCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Chris DunhamDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Alexandra FokCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Martin JonesCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-9636-376X
Anna F LeeDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-6703-0656
Yussanne MaCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Richard A MooreCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-0905-2742
Karen L MungallCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Paul C RogersDepartment of Pediatrics, BC Children's Hospital and Research Institute, Vancouver, BC, Canada.
Kasmintan A SchraderDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-7413-4314
Alice ViraniDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Kathleen WeeCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Sean S YoungDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-5240-1450
Yongjun ZhaoCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.
Steven J M JonesCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0003-3394-2208
Janessa LaskinDepartment of Medical Oncology, BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-0161-9329
Marco A MarraCanada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-7146-7175
Shahrad R RassekhDepartment of Pediatrics, BC Children's Hospital and Research Institute, Vancouver, BC, Canada. rrassekh@cw.bc.ca.ORCID http://orcid.org/0000-0001-8005-2641

Funding

Canada Foundation for Innovation (Fondation canadienne pour l'innovation) 20070, 30981, 30198, 33408 and 35444Genome British Columbia B20POGGenome Canada (Génome Canada) 202SEQ, 212SEQ, 262SEQ, 12002
6 · The paper itself

Abstract

The role for routine whole genome and transcriptome analysis (WGTA) for poor prognosis pediatric cancers remains undetermined. Here, we characterize somatic mutations, structural rearrangements, copy number variants, gene expression, immuno-profiles and germline cancer predisposition variants in children and adolescents with relapsed, refractory or poor prognosis malignancies who underwent somatic WGTA and matched germline sequencing. Seventy-nine participants with a median age at enrollment of 8.8 y (range 6 months to 21.2 y) are included. Germline pathogenic/likely pathogenic variants are identified in 12% of participants, of which 60% were not known prior. Therapeutically actionable variants are identified by targeted gene report and whole genome in 32% and 62% of participants, respectively, and increase to 96% after integrating transcriptome analyses. Thirty-two molecularly informed therapies are pursued in 28 participants with 54% achieving a clinical benefit rate; objective response or stable disease ≥6 months. Integrated WGTA identifies therapeutically actionable variants in almost all tumors and are directly translatable to clinical care of children with poor prognosis cancers.

Indexed as

DNA Copy Number VariationsGene Expression ProfilingNeoplasmsAdolescentChildChild, PreschoolFemaleGenetic Predisposition to DiseaseGenome, HumanGerm-Line MutationHumansInfantMaleMutationPrognosisTranscriptome

Identifiers

PMID38755180
PMCPMC11099106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.